Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma

Multiple myeloma is commonly associated with genomic alterations that result in hyperactivation of the mitogen-activated protein kinase pathway. BRAF (v-raf murine sarcoma viral oncogene homolog B) V600E activating mutations have been observed in 4% of multiple myeloma cases. Patients with BRAF V600Eemutated myeloma may have an unusually aggressive clinical course associated with prominent extramedullary disease and a short duration of response to standard therapies. Vemurafenib, a BRAF V600Eespecific inhibitor and an FDA approved agent for treatment of melanoma, also has clinical activity in BRAF V600E mutationepositive multiple myeloma.